International Journal of Physiology, Pathophysiology and Pharmacology. Vol. 4, no. 1. (2012): 1–9.
49. Ma Y, Nie H, Sheng C, Chen H, Wang B, Liu T, Shao J, He X, Zhang T, Zheng C, Xia W, and Ying W. “Roles of Oxidative Stress in Synchrotron Radiation X-RayInduced Testicular Damage of Rodents.” International Journal of Physiology Pathophysiology and Pharmacology. Vol. 4, no. 2. (2012): 108–114.
50. Fessel JP, Oldham W. “Pyridine Dinucleotides from Molecules to Man.” Antioxidants & Redox Signaling. Vol. 28, no. 3. (January 20, 2018): 180–212.
51. Rajman L, Chwalek K, Sinclair DA. “Therapeutic Potential of NAD-Boosting Molecules: The in Vivo Evidence.” Cellular Metabolism. Vol. 27, no. 3. (March 6, 2018): 529–547.
52. Erdelyi K, Bakondi E, Gergely P, Szabó C, Virág L. “Pathophysiologic Role of Oxidative Stress-Induced Poly(ADP-ribose) Polymerase-1 Activation: Focus on Cell Death and Transcriptional Regulation.” Cellular and Molecular Life Sciences. Vol. 62, no. 7–8. (April 2005): 751–759.
53. Clement J, Wong M, Poljak A, Sachdev P, Braidy N. “The Plasma NAD+ Metabolome Is Dysregulated in ‘Normal’ Aging. Rejuvenation Research. Vol. 22, no. 2. (April 2019): 121–130. doi: 10.1089/rej.2018.2077.
54. Laliotis GP, BizelisI, Rogdakis R. “Comparative Approach of the de novo Fatty Acid Synthesis (Lipogenesis) between Ruminant and Non Ruminant Mammalian Species: From Biochemical Level to the Main Regulatory Lipogenic Genes.” Current Genomics. Vol. 11, no. 3. (May 2010): 168–183. doi: 10.2174/138920210791110960.
55. Fang EF, Lautrup S, Hou Y, Demarest TG, Croteau DL, Mattson MP, Bohr VA. “NAD(+) in Aging: Molecular Mechanisms and Translational Implications.” Trends in Molecular Medicine. Vol. 23, no. 10. (October 2017): 899–916. doi: 10.1016/j.molmed.2017.08.001.
56. Katsyuba E, Auwerx J. “Modulating NAD(+) Metabolism, from Bench to Bedside.” EMBO Journal. Vol. 36, no. 18. (September 15, 2017): 2670–2683. doi: 10.15252/embj.201797135.
57. Rajman L, Chwalek K, Sinclair DA. “Therapeutic Potential of NAD-Boosting Molecules: The in vivo Evidence.” Cellular Metabolism. Vol. 27, no. 3. (March 6, 2018): 529–547.
58. Yoshino J, Baur JA, Ima SI. “NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR.” Cellular Metabolism. Vol. 27, no. 3. (March 6, 2018): 513–528.
59. Grant RS, Kapoor V. “Murine Glial Cells Regenerate NAD, After Peroxide-Induced Depletion, Using Either Nicotinic Acid, Nicotinamide, or Quinolinic Acid as Substrates.” Journal of Neurochemistry. Vol. 70, no. 4. (April 1998): 1759–1763.
60. Elvehjem CA, Madden RJ, Strong FM, Woolley DW. “The Isolation and Identification of the Anti-Black Tongue Factor.” Nutrition Reviews. Vol. 32, no. 2. (February 1974): 48–50.
61. Mannar V, Hurrell R., editors. Food Fortification in a Globalized World. London: Academic Press/Elsevier, 2017.
62. Kirkland JB. “Niacin Status and Treatment-Related Leukemogenesis.” Molecular Cancer Therapeutics. Vol. 8, no. 4. (April 2009): 725–732.
63. Kirkland JB. “Niacin Status Impacts Chromatin Structure.” Journal of Nutrition. Vol. 139, no. 12. (December 2009): 2397–2401.
64. Kirkland JB. “Niacin Status and Genomic Instability in Bone Marrow Cells; Mechanisms Favoring the Progression of Leukemogenesis.” Subcellular Biochemistry. Vol. 56. (2012): 21–3.
65. Kirkland JB. “Niacin Requirements for Genomic Stability.” Mutation Research. Vol. 733, no. 1–2. (May 1, 2012): 14–20.
66. Menon RM, Gonzalez MA, Adams MH, Tolbert DS, Leu JH, Cefali EA. “Effect of the Rate of Niacin Administration on the Plasma and Urine Pharmacokinetics of Niacin and Its Metabolites.” Journal of Clinical Pharmacology. Vol. 47, no. 6. (June 2007): 681–768.
67. Peled T. “Nicotinamide, a SIRT1 Inhibitor, Inhibits Differentiation and Facilitates Expansion of Hematopoietic Progenitor Cells with Enhanced Bone Marrow Homing and Engraftment.” Experimental Hematology. Vol. 40, no. 4. (April 2012): 342–355.
68. Gaikwad A, Long DJ 2nd, Stringer JL, Jaiswal AK. “In Vivo Role of NAD(P)H: Quinone Oxidoreductase 1 (NQO1) in the Regulation of Intracellular Redox State and Accumulation of Abdominal Adipose Tissue.” Journal of Biological Chemistry. Vol. 276, no. 25. (June 22, 2001); 22559–25564.
69. Yaku K, Okabe K, Nakagawa T. “NAD Metabolism: Implications in Aging and Longevity.” Ageing Research Reviews. Vol. 47. (November 2018): 11–17. doi: 10.1016/j.arr.2018.05.006.
70. Müller F. “Flavin Radicals: Chemistry and Biochemistry.” Free Radical Biology and Medicine. Vol. 3, no. 3. (1987): 215–230.
71. Garber K. “Biochemistry: A Radical Treatment.” Nature. Vol. 489. (2012) S4–6.
72. Mathew ST, Bergström P, Hammarsten O. “Repeated Nrf2 Stimulation Using Sulforaphane Protects Fibroblasts from Ionizing Radiation.” Toxicology and Applied Pharmacology. Vol. 276, no. 3. (May 2014): 188–194.
73. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Sonis ST, Ward KW. “Topical Application of the Synthetic Triterpenoid RTA 408 Protects Mice from Radiation-Induced Dermatitis.” Radiation Research. Vol. 181, no. 5. (May 2014): 512–520.
74. Iranshahy M, Iranshahi M, Abtahi SR, Karimi G. “The Role of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatoprotective Activity of Natural Products: A Review.” Food and Chemical Toxicology. Vol. 120. (October 2018): 261–276. doi: 10.1016/j.fct.2018.07.024.
75. O’Connell MA, Hayes JD. “The Keap1/Nrf2 Pathway in Health and Disease: From the Bench to the Clinic.” Biochemical Society Transactions. Vol. 43. (2015): 687–689.
76. Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. “Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study.” Chest. Vol. 151, no. 6. (June 2017): 1229–1238. doi: 10.1016/j.chest.2016.11.036.
77. Hershey TB, Kahn JM. “State Sepsis Mandates – A New Era for Regulation of Hospital Quality.” New England Journal of Medicine. Vol. 376, no. 24. (June 15, 2017): 2311–2313. doi: 10.1056/NEJMp1611928.
78. Shin TG, Kim YJ, Ryoo SM, Hwang SY, Jo IJ, Chung SP, Choi SH, Suh GJ, Kim WY. “Early Vitamin C and Thiamine Administration to Patients with Septic Shock in Emergency Departments: Propensity Score-Based Analysis of a Before-and-After Cohort Study.” Journal of Clinical Medicine. Vol. 8, no. 1. (January 16, 2019): E102. doi: 10.3390/jcm8010102.
79. Balakrishnan M, Gandhi H, Shah K, Pandya H, Patel R, Keshwani S, Yadav N. “Hydrocortisone, Vitamin C and Thiamine for the Treatment of Sepsis and Septic Shock Following Cardiac Surgery.” Indian Journal of Anaesthesia. Vol. 62, no. 12. (December 2018): 934–939. doi: 10.4103/ija.IJA_361_18.
80. Marik PE. “Hydrocortisone, Ascorbic Acid and Thiamine (HAT Therapy) for the Treatment of Sepsis. Focus on Ascorbic Acid.” Nutrients. Vol. 10, no. 11. (November 14, 2018): E1762. doi: 10.3390/nu10111762.
81. Moskowitz A, Andersen LW, Huang DT, Berg KM, Grossestreuer AV, Marik PE, Sherwin RL, Hou PC, Becker LB, Cocchi MN, Doshi P, Gong J, Sen A, Donnino MW. “Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis: A Review of the Biologic Rationale and the Present State of Clinical Evaluation.” Critical Care. Vol. 22, no. 1. (October 29, 2018): 283. doi: 10.1186/s13054-018-2217-4.
82. Surh YJ, Kundu JK, Na HK. “Nrf2 as a Master Redox Switch in Turning on the Cellular Signaling Involved in the Induction of Cytoprotective Genes by Some Chemopreventive Phytochemicals.” Planta Medica. Vol. 74, no. 13. (October 2008): 1526–1539.
83. Nakagawa F, Morino K, Ugi S, Ishikado A, Kondo K, Sato D, Konno S, Nemoto K, Kusunoki C, Sekine O, Sunagawa A, Kawamura M, Inoue N, Nishio Y, Maegawa H. “4-Hydroxy Hexenal Derived from Dietary n-3 Polyunsaturated Fatty Acids Induces Anti-Oxidative Enzyme Heme Oxygenase-1 in Multiple Organs.” Biochemical and Biophysical Research Communications. Vol. 443, no. 3. (2014): 991–996.
84. Kumar H, Kim IS, More SV, Kim BW, Choi DK. “Natural Product-Derived Pharmacological Modulators of Nrf2/ARE Pathway for Chronic Diseases.” Natural Products Reports. Vol. 31, no. 1. (January 2014): 109–139.
85. Lewis KN, Mele J, Hayes JD, Buffenstein R. “Nrf2, a Guardian of Healthspan and Gatekeeper of Species Longevity.” Integrative and Comparative Biology. Vol. 50, no. 5. (November 2010): 829–843.
86. Kapeta S, Chondrogianni N, Gonos ES. “Nuclear Erythroid Factor 2-Mediated Proteasome Activation Delays Senescence in Human Fibroblasts.” Journal of Biological Chemistry. Vol. 285, no. 11. (March 12, 2010): 8171–8184.
87. Jódar L, Mercken EM, Ariza J, Younts C, González-Reyes JA, Alcaín FJ, Burón I, de Cabo R, Villalba JM. “Genetic Deletion of Nrf2 Promotes Immortalization and Decreases Life Span of Murine Embryonic Fibroblasts.” Journals of Gerontology. Series A: Biological Sciences and Medical Sciences. Vol. 66A, no. 3. (March 2011): 247–256.
88. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K, Nakayama KI, Ide T, Saya H, Hara E. “Mitogenic Signalling and the p16INK4a-Rb Pathway Cooperate to Enforce Irreversible Cellular Senescence.” Nature Cell Biology. Vol. 8, no. 11. (2006): 1291–1297.
89. Gounder SS, Kannan S, Devadoss D, Miller CJ, Whitehead KJ, Odelberg SJ. Firpo MA, Paine R 3rd, Hoidal JR, Abel ED, Rajasekaran NS. “Impaired Transcriptional Activity of Nrf2 in Age-Related Myocardial Oxidative Stress Is Reversible by Moderate Exercise Training.” PLoS One. Vol. 7, no. 9. (2012): e45697.
90. Pall ML, Levine S. “Nrf2, a Master Regulator of Detoxification and also Antioxidant, Anti-Inflammatory and Other Cytoprotective Mechanisms, Is Raised by Health Promoting Factors.”